WO2024257051 - COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS (TTFIELDS) AND THIOREDOXIN/GLUTATHIONE INHIBITORS
National phase entry is expected:
Publication Number
WO/2024/257051
Publication Date
19.12.2024
International Application No.
PCT/IB2024/055862
International Filing Date
14.06.2024
Title **
[English]
COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS (TTFIELDS) AND THIOREDOXIN/GLUTATHIONE INHIBITORS
[French]
COMPOSITIONS, SYSTÈMES ET MÉTHODES DE TRAITEMENT DU CANCER À L'AIDE DE CHAMPS DE TRAITEMENT DE TUMEUR (TTFIELDS) ET D'INHIBITEURS DE THIORÉDOXINE/GLUTATHION
Applicants **
NOVOCURE GMBH
Inventors
ENGELMAN, Rotem
ABDULKARIM, Bassam
Priority Data
63/508,346
15.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2145 | |
| EPO | Filing, Examination, Granting | 8591 | |
| Japan | Filing, Examination, Granting | 2170 | |
| South Korea | Filing, Examination, Granting | 2060 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,706
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Compositions, kits, systems, and methods for reducing viability of cancer cells and treating cancer, as well as reducing a volume of a tumor and/or preventing an increase in volume of a tumor present in a body of a living subject, are disclosed. Also disclosed are methods of increasing reactive oxygen species (ROS) in cancer cells, along with methods of enhancing cytotoxicity of at least one thioredoxin reductase inhibitor and/or at least one glutathione inhibitor against cancer cells. The systems and methods involve application of an alternating field in combination with administration of at least one composition comprising at least one thioredoxin reductase inhibitor and/or at least one glutathione inhibitor.[French]
La divulgation concerne des compositions, des kits, des systèmes et des méthodes de réduction de la viabilité des cellules cancéreuses et de traitement du cancer, ainsi que des méthodes de réduction du volume d'une tumeur et/ou de prévention d'une augmentation du volume d'une tumeur présente dans un corps d'un sujet vivant. La divulgation concerne également des méthodes d'augmentation d'espèces réactives de l'oxygène (ROS) dans des cellules cancéreuses, ainsi que des méthodes d'amélioration de la cytotoxicité d'au moins un inhibiteur de thiorédoxine réductase et/ou d'au moins un inhibiteur de glutathion contre des cellules cancéreuses. Les systèmes et les méthodes impliquent l'application d'un champ alternatif en combinaison avec l'administration d'au moins une composition comprenant au moins un inhibiteur de thiorédoxine réductase et/ou au moins un inhibiteur de glutathion.